Fasiglifam

DB12491InvestigationalSmall molecule

Fasiglifam has been used in trials studying the treatment of Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Diabetes Mellitus, Type 2.

Chemical structure of Fasiglifam
Mechanism
Curator reviewed
Formula / weight
C29H32O7S · 524.63 g/mol (avg)

Resolves to

Compound
UNIIGLP1W4JXAHCAS1000413-72-8ChEMBLCHEMBL1829174PubChem24857286
Structure
InChIKeyBZCALJIHZVNMGJ-HSZRJFAPSA-NSMILESCC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C1=CC=CC(COC2=CC=C3[C@H](CC(O)=O)COC3=C2)=C1
Targets
O14842FFAR1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Fasiglifam, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In